Marshall Wace North America’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-16,995
Closed -$496K 1462
2020
Q4
$496K Buy
16,995
+204
+1% +$5.28K ﹤0.01% 1085
2020
Q3
$370K Buy
+16,791
New +$428K ﹤0.01% 1029
2020
Q1
Sell
-2,312
Closed -$56K 1182
2019
Q4
$56K Sell
2,312
-32,580
-93% -$686K ﹤0.01% 1143
2019
Q3
$596K Buy
+34,892
New +$558K ﹤0.01% 783
2018
Q3
Sell
-114,795
Closed -$2.27M 890
2018
Q2
$2.27M Buy
+114,795
New +$2.52M 0.01% 735
2017
Q4
Sell
-202,215
Closed -$5.46M 1339
2017
Q3
$5.46M Buy
+202,215
New +$4.48M 0.03% 520

Other funds holding ACLS

Marshall Wace North America's ACLS Position: Q1 2021 in Review

Marshall Wace North America sold out of Axcelis (ACLS) in Q1 2021, closing a stake of 16,995 shares — an estimated $496K sold.

Marshall Wace North America first reported a position in ACLS in Q3 2017 and held it in 6 quarters. The position peaked at $5.46M in Q3 2017. 193 funds tracked by Wall St. Rank hold ACLS as of Q1 2021.

  • Marshall Wace North America reported no remaining Axcelis position as of Q1 2021 after selling out during the quarter.
  • Marshall Wace North America sold 16,995 Axcelis shares in Q1 2021, an estimated $496K.
  • Marshall Wace North America first reported a position in Axcelis in Q3 2017 and held it in 6 quarters.
  • Marshall Wace North America's Axcelis position peaked at $5.46M in Q3 2017.
  • 193 funds tracked by Wall St. Rank held Axcelis as of Q1 2021.

Based on Marshall Wace North America's 13F filing for Q1 2021, filed 17 May 2021.